Patricia Powell, Ph.D., was appointed Deputy Director of the National Institute on Alcohol Abuse and Alcoholism (NIAAA) in 2017 having served as Acting Deputy Director since 2015. In this role she works closely with NIAAA's Director to set the vision for the Institute and facilitate its implementation in both the extramural and intramural programs. She and the Director work in concert on strategic goals, funding decisions, alignment of priorities and enhancing staff career opportunities. Dr.

Dr. Fenkel is a Professor of Medicine at Sidney Kimmel Medical College at Thomas Jefferson University in Philadelphia, PA, USA. He is the Director of the Jefferson Viral Hepatitis Center and Associate Medical Director of Liver Transplantation at Thomas Jefferson University Hospital. He is the current Vice-Chair of the AASLD's Hepatitis C Special Interest Group.

Melissa Palmer, MD has been a Hepatologist for over 35 years and is an experienced biotech/pharma executive. She is currently CEO of Liver Consulting LLC, consulting exclusively to biotech and pharmaceutical companies on hepatology-related issues such as: innovative trial designs for all liver diseases including metabolic dysfunction-associated steatotic hepatitis (MASH), PBC, Hepatitis B and D, primary sclerosing cholangitis (PSC), alcohol- associated liver disease and all aspects of liver disease drug development from pre-IND to NDA.

Jennifer Onwochei is a Transplant Hepatologist at Northwell Health with a commitment to advancing patient care and medical education. In addition to providing specialized care for patients with complex liver diseases and those undergoing liver transplantation, she has a strong interest in public health, community outreach, and global health initiatives aimed at improving healthcare access and outcomes across diverse populations.

Medical Director, Liver Transplant Program. Johns Hopkins University School of Medicine

Chemical Biology PhD Candidate at the University of Michigan, working under Dr. Jonathan Sexton. Focused on using patient-derived liver organoids to model clinically significant hepatotoxicity in an in-vitro model system.

Dr. Dina Halegoua-De Marzio is a transplant hepatologist and is currently a Professor of Medicine at Sidney Kimmel Medical College at Thomas Jefferson University. She completed her residency in internal medicine and fellowships in gastroenterology and transplant hepatology at Thomas Jefferson University Hospital (TJUH). She developed the first adult Fatty Liver Center in the Delaware Valley and currently serves as its director. She also serves as the Director of GI Research at TJUH and Associate Chief for the Division of Gastroenterology and Hepatology at TJUH.

Dr. Hayashi is the Associate Director of DILI within the Division of Hepatology and Nutrition, FDA. He received his Bachelor of Arts in microbiology at UCLA and MD at University of California (UC), San Diego. After completing residency and gastroenterology fellowship at UC Davis in Sacramento, California, he completed a clinical research fellowship in the Liver Diseases Section, NIDDK, NIH. He then completed a transplant fellowship at the University of Colorado, Denver. He completed a Master of Public Health at Saint Louis University (SLU), St.

Robert Wong, MD, MS, FACG, FAASLD is a Clinical Associate Professor of Medicine (Affiliated) in the Division of Gastroenterology and Hepatology, Stanford University School of Medicine, and staff physician in the Gastroenterology and Hepatology Section at Veterans Affairs Palo Alto Healthcare System. He completed gastroenterology and hepatology fellowship at Stanford University School of Medicine, where he also completed a Master's in Epidemiology and Clinical Research.

Associate Professor of Medicine. Gastroenterologist and Transplant Hepatologist. Mayo Clinic Florida